For patients diagnosed with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma:

CLDN18.2: Identify and interpret with confidence

Claudin 18.2 (CLDN18.2) identifies a previously undefined population of patients with G/GEJ adenocarcinoma. CLDN18.2 is detected via IHC testing.1